Principal Investigator:
Prof.ssa Maria Gabriella Ferrandina
Target:
Aim of the project (FPG and ENEA) is to identify a predictive gene signature of chemoradiation treatment response in cervical cancer, through bioinformatic analysis and machine learning algorithms.
Publications:
- Buttarelli M, Babini G, Raspaglio G, Filippetti F, Battaglia A, Ciucci A, Ferrandina G, Petrillo M, Marino C, Mancuso M, Saran A, Villani ME, Desiderio A, D’Ambrosio C, Scaloni A, Scambia G, Gallo D. A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer. J Exp Clin Cancer Res. 2019 Jun 26;38(1):279. doi: 10.1186/s13046-019-1268-y.
- Leonardi S, Buttarelli M, De Stefano I, Ferrandina G, Petrillo M, Babini G, Scambia G, Marino C, Mancuso M, Gallo D. The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer. Oncotarget. 2017 Oct 9;8(55):94247-94258. doi: 10.18632/oncotarget.21686. eCollection 2017 Nov 7.
As a result of collaboration between FPG and ENEA, the molecular signature identified has been allowed for issuance as a patent.